He recommended to Sanofi to test first children to determine who are seronegative
before inoculating them with Dengvaxia.
Halstead told the Senate panel he tried to halt the government from administering the Dengvaxia to seronegative
individuals due to a greater risk of exposing them to serious dengue.
Halstead said that Dengvaxia should not be administered to seronegative
individuals, or people who had never been infected with the dengue virus.
Facing the good government and health committees of the House of Representatives, which are inquiring into the Dengvaxia controversy, Aquino said he had no way of knowing in 2015 of the risks posed by the vaccine on seronegative
recipients, or people who had no previous exposure to the dengue virus.
It was only on this announcement that Sanofi Pasteur revealed that Dengvaxia poses a heightened risk of contracting severe dengue to seronegative
individuals,' Duque added.
First, the Committee wants the Departments of Health (DOH), of Education (DepEd), and of the Interior and Local Government (DILG) to work together and submit the list of ALL the names of the people injected with Dengvaxia and classify them whether they are seropositive or seronegative
, including their age.
21-24) Although many institutions have adopted universal leukoreduction policies, the question of providing leukoreduced blood products that are also CMV seronegative
for specific at-risk patient populations has remained unanswered.
In addition, we evaluated the demographic, epidemiologic, clinical, and serological features of family members and compared seropositive and seronegative
In patients with seropositive RA the peripheral helper cells accounted for up to 25% of all CD+4 T-cells, but were not increased in seronegative
RA, psoriatic arthritis or juvenile idiopathic arthritis.
Result of The IDO level in seropositive leprosy subjects was higher compared to those who were seronegative
(p = 0.
Although age is a critical risk factor for severe WNV infection (3,9), the mean age of seropositive and seronegative
nonimmunosuppressed participants did not differ significantly (Table).
In Phase I and II studies, the vaccine candidate induced neutralizing antibody responses against all four dengue virus serotypes across age groups and in both seropositive and seronegative
individuals with no observed safety concerns.